QNRX Market Outperform Price Target !!

Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd.

Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide.

This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome.

My price target is the 12usd resistance.